Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Phase 1 Unknown

60 enrolled

Lymphoid

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03815682 2022-12-06

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

Phase 1 Terminated

23 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Phase 1 Completed

80 enrolled

BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

MK-1454-001

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NEON-2

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Phase 1 First-in-human Study of JS014

Safety Study of SEA-CD40 in Cancer Patients

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab